(Total Views: 304)
Posted On: 09/28/2018 10:01:14 AM
Post# of 88
***PKTX..We GOT PR News..
ProtoKinetix Begins Cardiovascular Research
Press Release | 09/28/2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
(OTCQB
KTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences.
Dr. Thomas Pulinilkunnil, Associate Professor, Department of Biochemistry and Molecular Biology, Dalhousie University is the principal investigator on this project. Pulinilkunnil laboratory will screen and examine the therapeutic utility of PKX-001 (AAGP®) against inflammatory, hypertrophic and ischemic pathologies in the heart . Upon the completion of this phase of testing, pre-clinicalscreening of organ preservation and metabolic effects of PKX-001 will be undertaken in transplant ready cardiac tissue. The overarching goal of this project is to develop PKX-001 as a cardioprotective agent with wide ranging applications in cardiovascular medicine.
ProtoKinetix Begins Cardiovascular Research
Press Release | 09/28/2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
(OTCQBKTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences. Dr. Thomas Pulinilkunnil, Associate Professor, Department of Biochemistry and Molecular Biology, Dalhousie University is the principal investigator on this project. Pulinilkunnil laboratory will screen and examine the therapeutic utility of PKX-001 (AAGP®) against inflammatory, hypertrophic and ischemic pathologies in the heart . Upon the completion of this phase of testing, pre-clinicalscreening of organ preservation and metabolic effects of PKX-001 will be undertaken in transplant ready cardiac tissue. The overarching goal of this project is to develop PKX-001 as a cardioprotective agent with wide ranging applications in cardiovascular medicine.
(0)
(0)
